a leader in the worldwide diabetes and obesity care market, has been witnessing stellar performance of its GLP-1 agonist, semaglutide. Apart from the oral formulation of the drug sold as Rybelsus ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

The study showed that Rybelsus, the company's oral form of semaglutide, slashed the risk of major cardiovascular events by 14% in type 2 diabetes patients who also face cardiovascular or kidney ...

So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...

The survey of 1,078 adults, carried out by Ipsos, found 24% of people would use weight-loss jabs if they were provided for ...

The study included 9,650 patients with type 2 diabetes who also have cardiovascular complexities or chronic kidney disease. According to data from the trial, Rybelsus helped reduce the risk of ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

Lexaria Bioscience (LEXX) received partial 12-week blood sugar results from the recently completed animal study WEIGHT-A24-1. The company said, ...